AVERITAS PHARMA Trademark

Trademark Overview

On Tuesday, April 26, 2022, a trademark application was filed for AVERITAS PHARMA with the United States Patent and Trademark Office. The USPTO has given the AVERITAS PHARMA trademark a serial number of 97978677. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Wednesday, August 28, 2024. This trademark is owned by Averitas Pharma, Inc.. The AVERITAS PHARMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, and neurological diseases and disorders
averitas pharma

General Information

Serial Number97978677
Word MarkAVERITAS PHARMA
Filing DateTuesday, April 26, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateWednesday, August 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 28, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of viral, metabolic, endocrine, and neurological diseases and disorders
NOT AVAILABLE"PHARMA"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2023
Primary Code005
First Use Anywhere DateTuesday, November 27, 2018
First Use In Commerce DateFriday, March 29, 2019

Trademark Owner History

Party NameAveritas Pharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMorristown, NJ 07960
Party NameAveritas Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMorristown, NJ 07960

Trademark Events

Event DateEvent Description
Friday, April 29, 2022NEW APPLICATION ENTERED
Monday, May 2, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 21, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, February 21, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, February 14, 2023ASSIGNED TO EXAMINER
Tuesday, February 21, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, February 21, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 28, 2023PUBLISHED FOR OPPOSITION
Tuesday, March 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 23, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, November 20, 2023SOU EXTENSION 1 FILED
Monday, November 20, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 2, 2024DIVISIONAL REQUEST RECEIVED
Thursday, May 2, 2024SOU EXTENSION 2 GRANTED
Thursday, May 2, 2024SOU EXTENSION 2 FILED
Thursday, May 2, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 2, 2024TEAS STATEMENT OF USE RECEIVED
Friday, May 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 10, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, June 11, 2024ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
Wednesday, August 7, 2024RESPONSE TO ITU OFFICE ACTION ENTERED
Tuesday, February 21, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, November 20, 2023SOU EXTENSION 1 GRANTED
Thursday, May 2, 2024USE AMENDMENT FILED
Thursday, May 2, 2024TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, August 7, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 7, 2024ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
Tuesday, August 13, 2024DIVISIONAL PROCESSING COMPLETE
Tuesday, August 13, 2024STATEMENT OF USE PROCESSING COMPLETE
Wednesday, August 28, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, August 28, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

pharma averitas neurological diseases disorders endocrine metabolic preparations treatment viral pharmaceutical